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OBJECTIVE — To examine and quantify from the societal perspective the impact of macro-
vascularcomorbidconditions(MVCCs)onhealthcareandproductivitycostsindiabeticpatients
in the U.S.
RESEARCH DESIGN AND METHODS — With use of the pooled Medical Expenditure
Panel Survey (MEPS) 2004 and 2006 data, a nationally representative adult sample (aged 18
years) was included in the study. Health care cost was measured by the annual health care
expenditure. Productivity cost was calculated from the lost productivity from missed work days
and additional bed days due to illness/injury based on the 2006 average national hourly wage.
Both 2004 and 2006 cost data were adjusted to 2006 dollars. Given the heavily right-skewed
distribution of the cost data, the generalized linear model with log-link function and  variance
was used to identify the relationship between MVCCs and costs after controlling for age, sex,
race, ethnicity, education, income, employment status, smoking status, health insurance, dia-
betes severity, and comorbidities. Negative binomial models were applied to analyze the out-
comes of missed work days and bed days. All statistics were adjusted using the proper sampling
weight from MEPS.
RESULTS — Compared with diabetic patients without MVCCs (n  3,320), those with
MVCCs (n  913) had statistically signiﬁcant higher annual health care costs (5,120 USD, P 
0.001), more missed work days (13.03 days, P  0.001), and more bed days (7.60 days, P 
0.025) per patient after controlling for differences in sociodemographics, smoking, diabetes
severity, and comorbidities. The marginal lost productivity cost was 2,388 USD annually per
patient.
CONCLUSIONS — From the U.S. societal perspective, MVCCs in diabetic patients are as-
sociated with increased health care and lost productivity costs.
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D
iabetes is one of the most prevalent
and costly chronic disease condi-
tions in the U.S. (1,2). In 2007, the
diabetes-related total cost was 174 billion
dollars in the U.S., including 116 billion
dollars in direct health care expense and
58 billion dollars in indirect cost for loss
ofworkproductivity(2).Patientswithdi-
abetes have an increased risk of develop-
ing vascular complications including
microvascular and macrovascular com-
plications (3). Among them, macrovascu-
lar complications are a major concern
because a substantial proportion of
deaths from diabetes results from these
complications. In 1999, 65% of deaths
in patients with type 2 diabetes were
caused by macrovascular disease (4). The
risk of macrovascular death in patients
with diabetes is double that in patients
without diabetes (5,6), and patients with
diabetes have the same risk of cardiovas-
cular death as patients with a history of
myocardial infarction (5,7).
Studieshaveshownthatmacrovascu-
lar comorbid conditions (MVCCs) are a
major driver of health care costs in pa-
tients with diabetes in the U.S. (8,9). Us-
ing a population-based sample, in 1988
Glauber and Brown (10) reported that
cardiovascular disease accounted for at
least 24% of the total health care costs in
patientswithdiabetescomparedwithjust
12% of the total health care costs in pa-
tients without diabetes. Nichols and
Brown (11) used 1999 data and reported
that the average health care costs for pa-
tients with both diabetes and cardiovas-
cular disease were 10,172 USD annually,
compared with 4,402 USD for those with
diabetes but without cardiovascular dis-
ease. Using 2003 data, Gandra et al. (12)
found that macrovascular disease nearly
tripledannualhealthcarecostsinpatients
with type 2 diabetes: 10,450 vs. 3,385
USD for those with and without macro-
vascular diseases, respectively. However,
all of these studies relied on claims data
from HMOs, which may not be represen-
tative of the U.S. national population. In
addition, certain important patient char-
acteristics, such as education and income
level, were not available in the databases.
Theinadequatecontrolofthesecovariates
can bias the quantiﬁed relationship be-
tween costs and MVCCs in diabetes.
There is also lack of data on the im-
pact of MVCCs on indirect costs resulting
from lost productivity for patients with
diabetes. Only one early study (13) ad-
dressedthistopicbyusingaggregatedna-
tional estimates. Nonetheless, to estimate
the full economic impact from the U.S.
societal perspective, both direct and indi-
rect costs must be included. The purpose
of the current study, therefore, was to ex-
aminetheeconomicimpactofMVCCson
patients with diabetes in a nationally rep-
resentative community-dwelling sample
of U.S. adults.
RESEARCH DESIGN AND
METHODS
Data source
The Medical Expenditure Panel Survey
(MEPS) is a U.S. nationally representative
survey maintained and cosponsored by
the Agency for Healthcare Research and
Quality (AHRQ). The MEPS household
survey collects detailed information on
individualsociodemographiccharacteris-
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gories of health care utilization. The
MEPS database provides national esti-
mates of health care expenditures for the
U.S. civilian noninstitutionalized popula-
tion. The survey uses an overlapping
panel design in which data are collected
throughpreliminarycontactsfollowedby
ﬁve subsequent rounds of interviews per
panel with a time lag of 4–5 months over
a2-yearperiod.Thepresentstudypooled
the 2004 and 2006 MEPS public use data
to achieve a more robust sample size; the
2006 data are the most recent MEPS data
that are publicly available. As the MEPS is
conducted in a different sample every
other year, the combined datasets con-
tained all unique subjects.
Our study focused on adult subjects
aged18years.TheMEPSsampledesign
includes stratiﬁcation, clustering, multi-
ple-stageselections,anddisproportionate
sampling (Hispanics and blacks are over-
sampled). The MEPS sampling weights
were available to adjust for the complex
design and questionnaire nonresponse
(14).
Variables of interest
We measured the direct cost by the total
health care expenditure of the calendar
year for each subject. The 2004 and 2006
costs were adjusted to 2006 dollars using
the medical care component of the con-
sumer price index. Indirect productivity
cost was calculated from both days of
work missed due to illness or injury and
additionalmisseddaysthatthestudysub-
jects spent in bed due to illness or injury.
In the MEPS, employed individuals were
asked in each round how many days of
work they missed due to illness or injury.
An additional bed day was the measure of
lost productivity for both employed and
unemployed individuals. The cost of
missed work days and additional bed
days was estimated on the basis of the
2006averagenationalhourlywageacross
U.S. occupations with an hourly wage of
19.29 USD (15). Because MEPS does not
differentiate between missed full and par-
tial days, we assumed each missed day to
be6hwiththeindirectcostof115.74/day
USD (19.29 USD/h  6 h). The indirect
cost per person was the product of the
indirectcostperdayandthetotalnumber
of missed work days and additional bed
days for an individual within a year.
Weusedclinicalclassiﬁcationcatego-
ries (CCCs) deﬁned in the MEPS to rep-
resent disease conditions. CCCs were
generated using the clinical classiﬁcation
software by AHRQ (16). It aggregates the
ICD-9-CM conditions and V-codes into
260 mutually exclusive clinically homo-
geneous categories. We used CCC 49 “di-
abetes without complication” and CCC
50 “diabetes with complication” to iden-
tify patients with diabetes. The MVCCs
were deﬁned using CCC codes 100, 101,
104, and 108–115, which included car-
diovascular disease (ischemic heart dis-
ease, congestive heart failure, aortic/
visceral/peripheral aneurysms, visceral
atherosclerosis, and peripheral vascular
disease) and cerebrovascular disease
(strokes and transient ischemic attacks).
Controlled covariates
To control for confounding, sociodemo-
graphic patient characteristics including
age, sex, race, Hispanic ethnicity, educa-
tion, income level, employment status,
health insurance, and smoking status
were included in the models. Race was
categorized into whites, blacks, Asians,
and all others. The education level, based
on years of education, was categorized as
no school (0 year), elementary grades
(1–8 years), high school grades (9–11
years), high school graduation (12 years),
college education (13–16 years), and
more (16 years). The income level was
deﬁned as a percentage of the poverty
level and grouped into ﬁve categories:
negative or poor (100%), near poor
(100–125%), low income (125–
200%), middle income (200–400%),
and high income (400%). The health
insurance variables include having Medi-
care, Medicaid, a private HMO, other pri-
vate plans, and uninsured during the
year.Potentialoverlappingofdifferentin-
surance types was allowed because a sub-
ject might have more than one type of
insurance, for example, dual Medicare
and Medicaid status. Thus, the estimated
coefﬁcient on any insurance type should
be interpreted as the marginal difference
between subjects with this insurance type
and those without.
We used comorbidity software, an
algorithm that uses Elixhauser’s coding
algorithms (17) to create comorbidity
variables for each individual, to calcu-
late comorbidity. Based on the ICD-
9-CM codes in the administrative data,
the comorbidity software is newly de-
veloped with 30 unique comorbid cate-
gories. A recent version (3.4) of the
comorbidity software from AHRQ was
used in the study (18). If subjects
claimed to have disease conditions
other than those listed in the comorbid-
ity software, an additional category was
created to differentiate them from sub-
jects without any other disease condi-
tions. Therefore, we included the total
number of comorbidity categories (dia-
betes and MVCCs excluded) to control
for comorbidities in the analyses. In ad-
dition, we included three dummy vari-
ables, nephropathy, retinopathy, and
neuropathy, to control for the severity
of diabetes.
Statistical analysis
This was a retrospective cross-sectional
analysis. The main focus of the study
was the incremental economic impact
(including both direct health care cost
and indirect productivity cost) of
MVCCs on patients with diabetes. Cost
data are typically right-skewed because
a relatively small proportion of patients
incur extremely high costs. Even if the
estimate is unbiased from the linear re-
gression models, it could be unstable,
given the skewness and kurtosis of the
data distribution, and inefﬁcient due to
the heteroscedasticity. Such problems
were dealt with by logarithmic or other
transformation of the cost data (19).
However, this introduces additional
problems while retransforming back to
the dollar value (20). To avoid these
problems, we used the generalized lin-
ear model with log-link and gamma
variance functions (21) to identify the
relationship between MVCCs and costs
after controlling for covariates.
We used negative binomial models to
estimate the impact of MVCCs on missed
work days and additional bed days. The
marginal effects of dummy variables in
both generalized linear model and nega-
tive binomial models were estimated us-
ing the method of recycled predictions
(22).Togeneralizethestudyresultstothe
U.S. population, the complex sampling
design of the MEPS was taken into ac-
count using the speciﬁed sample weight,
variance estimation stratum, and primary
sampling unit (clustering).
RESULTS— TheMEPS2004and2006
had46,617adultsintotal,ofwhich4,233
(8.0% with weight adjustment) were pa-
tients with diabetes. There were 913
(22.0%) diabetic subjects with MVCCs
and the rest (n  3,320) without MVCCs.
Descriptive statistics for subjects with di-
abetes compared with the general adult
populationintheMEPSandsubjectswith
and without MVCCs among those with
diabetes are presented in Table 1. The av-
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tients with diabetes was 10,845 USD.
Among diabetic patients, the average an-
nual health care expenses were 18,434
and 8,707 USD for those with and with-
outMVCCs,respectively.Theaveragean-
nual missed work days due to illness or
injury and additional bed days for pa-
tients with diabetes were 6.7 and 13.0,
respectively, amounting to 2,285 USD in
indirect costs. The annual losses associ-
ated with indirect cost were 4,102 and
1,835 USD for diabetic patients with and
without MVCCs, respectively. Compared
with diabetes without MVCCs, those
with MVCCs were more likely to be
aged 65 years, male, non-Hispanic,
less educated, poor, and unemployed
and to have nephropathy, retinopathy,
and neuropathy.
We conducted the regression analy-
ses group I for all diabetic subjects (n 
4,233) and the regression group II for all
adultsubjects(n46,617).Themarginal
effects for the variables of interest are re-
ported in Table 2. The full regression re-
sults can be found in supplemental
Table 1—Population characteristics of U.S. adults (aged >18, MEPS 2004 and 2006)
All diabetes
Diabetes with
MVCC
Diabetes without
MVCC All subjects
n 4,233 913 3,320 46,617
Annual health care expense (USD) 10,845 18,434 8,707 4,240
Missed work days 6.74 11.65 5.90 3.67
Additional bed days 13.00 23.79 9.95 4.47
Annual indirect cost loss (USD) 2,285 4,102 1,835 942
Age-groups (%)
18–24 years 1.1 0.0 1.4 13.0
25–34 years 3.2 0.2 4.1 18.0
35–44 years 10.0 3.0 11.9 19.5
45–54 years 19.3 10.4 21.8 19.0
55–64 years 26.4 26.2 26.5 14.1
65 years 39.9 60.2 34.2 16.4
Female sex 51.5 46.0 53.1 51.7
Race (%)
White 77.8 79.3 77.3 81.7
Black 15.0 14.8 15.0 11.5
Asian 3.4 2.2 3.7 4.4
Other race 3.9 3.7 4.0 2.5
Hispanic ethnicity 12.9 9.3 13.9 12.8
Education
0 years 1.0 1.1 1.0 0.4
1–8 years 11.1 14.6 10.1 5.9
9–11 years 15.2 19.6 14.0 12.5
12 years 35.2 30.8 36.4 31.7
13–16 years 30.6 27.9 31.4 39.3
16 years 6.8 6.1 7.1 10.2
Income level (%)
Negative or poor 13.6 14.0 13.5 10.7
Near poor 6.7 7.4 6.5 4.1
Low income 16.5 18.5 15.9 13.0
Middle income 29.5 29.9 29.4 31.2
High income 33.7 30.2 34.7 40.9
Unemployed 53.1 71.7 47.9 26.8
Health insurance
Medicare 47.3 71.1 40.6 18.8
Medicaid 16.8 21.6 15.5 9.3
Private HMO 18.6 14.9 19.6 24.1
Other private plan 35.0 30.2 36.3 39.2
Uninsured 9.5 4.6 10.9 19.4
Currently smoke 14.9 13.1 15.4 18.7
Number of comorbitidy software
categories 2.53 3.28 2.31 1.55
Nephropathy 9.5 14.8 8.0 0.8
Retinopathy 18.9 26.6 16.7 2.1
Neuropathy 0.12 0.26 0.08 0.03
Data are % unless indicated otherwise.
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diabetesjournals.org/cgi/content/full/
dc09-1128/DC1.Comparedwithdiabeticpa-
tients without MVCCs, those with MVCCs
had statistically signiﬁcantly higher an-
nual health care expenses (5,120 USD,
P  0.001), more missed work days
(13.03, P  0.001), and more bed days
(7.60, P  0.025). The marginal lost pro-
ductivity cost was 2,388 USD annually
(115.74 USD/day  [13.03  7.60]
days). The total annual incremental cost
for MVCCs per diabetic subject, there-
fore, was 7,508 USD (5,120 USD in
health care expenses  2,388 USD in lost
productivity). Compared with individu-
als without diabetes and MVCCs, those
with diabetes or MVCCs spent signiﬁ-
cantly more on health care by 3,338 or
6,201USD(P0.001),respectively,and
hadmoremissedworkdaysandmorebed
days after controlling for sociodemo-
graphic characteristics, smoking status,
diabetes severity, and comorbidities. How-
ever, the interaction term between diabe-
tes and MVCCs was signiﬁcantly negative
on health care expense (2,880.07, P 
0.001), indicating that the incremental
health care cost of MVCCs for patients
with diabetes is lower than that for pa-
tients without diabetes.
Figure 1 illustrates the marginal im-
pact of diabetes without MVCCs, MVCCs
without diabetes, and diabetes with
MVCCs on both direct health care cost
and indirect productivity cost, relative to
subjectswithoutdiabetesandMVCCs,af-
ter controlling for sociodemographic
characteristics, smoking status, diabetes
severity, and comorbidities. The results
were derived from regression group II. It
is evident that the incremental economic
impactofdiabetesorMVCCsaloneissub-
stantial, and such an impact for patients
with both diabetes and MVCCs is even
more considerable than that for patients
with diabetes or MVCCs alone.
CONCLUSIONS— The results of
this nationally representative study in the
U.S. demonstrate that both diabetes and
macrovascular conditions are associated
with a considerable economic impact on
society, including both increased direct
health care cost and lost indirect produc-
tivity cost, and that the impact of MVCCs
on diabetic patients is also substantial.
We estimate that the incremental eco-
nomic impact of MVCCs on society is
7,500 USD annually per diabetic pa-
tient. In addition, the incremental health
care cost of MVCCs for patients with dia-
betes may actually be lower than that for
patients without diabetes. Our study pro-
videsup-to-datedatathatmayhelppolicy
makershaveabetterunderstandingofthe
economic impact of comorbid macrovas-
cularconditionsonpatientswithdiabetes
from the U.S. societal perspective.
Previouslypublishedresearchhasex-
amined the impact of MVCCs, primarily,
on direct health care costs in the U.S. In
general, similar associations have been
found (10–12). However, these studies
estimatedtheaveragehealthcarecostsfor
patients with and without diabetes and
MVCCs, whereas our study focused on
the incremental cost impact, which is
more useful from an economic stand-
point.Inaddition,thesepaststudieswere
conducted using HMO claims data, with
one study examining predominantly
older individuals (11) and another exam-
ining only subjects aged 65 years (12).
These study samples are probably differ-
entfromthegeneralcommunity-dwelling
population in the U.S. Speciﬁcally, Gan-
dra et al. (12) found that the health care
expenses for diabetic patients with and
without MVCCs were 10,450 and 3,385
USD per patient per year after matching
by age and sex. It implies an incremental
costof7,065USDinhealthcare,whichis
higherthanourestimateof5,120USD.In
addition, our regression results show that
the coefﬁcients of the HMO variable are
primarily positive and statistically signiﬁ-
cant,indicatingthattheHMOpatientson
average have higher health care and pro-
ductivity costs than those without HMO
insurance coverage. Therefore, the esti-
mated cost results using HMO data are
not a good representation of the commu-
nity-dwelling population and are proba-
bly overestimated.
Similar to our study, these previous
publications (10–12) have, to some ex-
tent, controlled for differences in baseline
characteristics between diabetic patients
with and without MVCCs. However, the
HMO claims data did not contain a full
array of sociodemographic information
such as race/ethnicity, education, and in-
come, as the MEPS data do. The inability
to control for these covariates may have
biased the quantiﬁed estimates between
MVCCs and costs of diabetes. Speciﬁ-
cally, in their study, Nichols and Brown
(11) suggested that the health care cost of
MVCCs for diabetic patients is higher
than that for patients without diabetes.
Onthecontrary,ourresultsindicatedthat
the incremental health care cost of
MVCCsforpatientswithdiabetesmayac-
tuallybelowerthanthatforpatientswith-
out diabetes. The cost outcomes in the
study of Nichols and Brown (11) were
primarily descriptive and only controlled
for age and sex. The difference between
our study ﬁndings and theirs could have
resulted from our control of more covari-
ates, especially diabetes severity and co-
morbidities. The additional sensitivity
analyses we conducted show that, even
without the control of education and in-
come, the direct cost would be underesti-
mated by 4% and indirect cost would be
overestimated by 7%. The MEPS is one of
the most detailed U.S. nationally repre-
sentative data sources available to exam-
ine questions related to medical
conditions, health care expense, and
missed work with comprehensive socio-
demographic information. More impor-
Table 2—Impact of diabetes and MVCCs on health care expense, missed work days, and
additional bed days due to illness/injury (marginal effect on the dependent variables)
Dependent variables
Annual health
care expense
($)
Missed work
days due to
illness/injury
Additional bed
days due to
illness/injury
Regression group I (all diabetes, n 
4,233)
Diabetes with MVCCs 5,119.93* 13.03* 7.60†
Diabetes MVCCs (reference)
Regression group II (all subjects, n 
46,617)
Diabetes 3,337.86* 0.90† 5.29†
MVCCs 6,201.16* 3.50* 5.29‡
Diabetes  MVCCs 2,880.07* 2.22 2.49
No diabetes or MVCCs (reference)
Age, sex, race, ethnicity, education, income, employment status, smoking status, health insurance, diabetes
severity, and number of comorbidity software categories were controlled for in all regressions; interaction
term of diabetes and MVCCs included for regression group II. *P  0.001; †P  0.05; ‡P  0.01.
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studies included the indirect productivity
cost in the outcome. The ﬁndings from
those studies, therefore, can be informa-
tive mostly from the third party payers’
perspective.Withtheinclusionofindirect
cost, our study evaluated the incremental
economic impact from the broader societal
perspective.
It is worth noting that 6 h/day was
assumed to calculate the loss of produc-
tivity cost because MEPS does not differ-
entiate between missed full and partial
days. If each day of lost work was as-
sumed to be 4 or 8 h, the marginal lost
productivitycostresultsin1,592or3,184
USD per patient, respectively, when dia-
betic patients with MVCCs are compared
with those without MVCCs. In addition,
Druss et al. (23) used 1996 MEPS data to
estimate the economic impact of ﬁve
chronic conditions including diabetes.
Both indirect productivity cost associated
with work loss and direct health care cost
were estimated. Nevertheless, the incre-
mental impact of MVCCs on diabetic pa-
tients was not a focus.
Our research is not without limita-
tions. First, the results of this study are
generalizable to the U.S. community-
dwelling adults but may not be relevant
for other populations. Second, the preva-
lenceofdiabetesandMVCCswereported
may be an underestimate of the true na-
tional prevalence because the MEPS is
basedonself-reporting.Previousresearch
has shown that self-reported conditions
may be underreported (24). In addition,
estimates suggest that up to 35% of indi-
viduals with diabetes have been undiag-
nosed (25). This downward bias may
result in smaller magnitude and signiﬁ-
cance of the estimates because the com-
parison group has no respective
conditions and implies that the true eco-
nomic impact may be even larger than we
estimated.Third,weusedthenationalav-
erage wage instead of actual wages to de-
termine the productivity cost. On the
otherhand,useofactualwageswouldim-
ply that there is no value to the lost time
forhomeworkers,retirees,andthosewho
have to abandon their job due to disease
conditions. Thus, application of the na-
tional average wage can better estimate
the opportunity cost of lost time from the
societal perspective. We also have to ac-
knowledge that, for unemployed individ-
ualsintheMEPSdata,thebeddaysdueto
illness/injury is the only measure of lost
productivity. Missed work days do not
apply to them. No record of missed work
daysimpliesthatourestimatecouldserve
asthelowerboundforwhichthetruelost
productivity for this group may be larger.
In addition, we have controlled for em-
ployment status in our analyses. This
should have adjusted for most, if not all,
Figure 1—Marginal impact of diabetes or MVCCs individually or combined on direct (A) and indirect (B) costs (controlling for age, sex, race,
ethnicity, education, income, employment status, smoking status, health insurance, diabetes severity, and number of comorbid categories).
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with unemployment.
There are other limitations to this re-
search. The MEPS did not collect cost in-
formation on over-the-counter drugs and
alternative care services. Because of the
smalldollaramountofthesecostsrelative
toothers,suchasinpatientandoutpatient
costs, the underestimation of overall di-
rect health care cost may be trivial. In ad-
dition, we included both patients with
type 1 and type 2 diabetes. Patients with
type 2 diabetes tend to be older and more
overweight and may have higher rates of
MVCCs and complications. By including
both types of diabetes, we may underes-
timatethecostsofdiabetesandMVCCsin
patients with type 2 diabetes.
In summary, previous research has
consistentlyshowntheimpactofdiabetes
and MVCCs alone and in combination on
health care cost. The results of this study
are mainly consistent with previous study
ﬁndings but add new ﬁndings by studying
the marginal impact of both the direct
health care cost and the indirect produc-
tivity cost of MVCCs on the U.S. society
for patients with diabetes. The marginal
economic impact of MVCCs on society
is 7,500 USD annually per diabetic
patient.
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